We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+58.68%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$105M
AUM Growth
Cap. Flow
+$85.5M
Cap. Flow %
81.8%
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 81.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CLVS
1
DELISTED
Clovis Oncology, Inc.
CLVS
$45.6M 43.63%
+814,833
New +$42.8M
FPRX
2
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$29.5M 28.2%
+1,092,152
New +$18.8M
AKAO
3
DELISTED
Achaogen Inc
AKAO
$16.7M 15.99%
+1,281,152
New +$13M
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$10.3M 9.86%
+1,048,601
New +$8.43M
KYTH
5
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$2.44M 2.33%
+70,376
New +$2.46M

Similar funds

Versant Venture Management's Q4 2014 Portfolio in Review

Q4 2014 is the first quarter with a 13F filing on record for Versant Venture Management, which disclosed 5 positions worth $105M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Clovis Oncology, Inc.: 814,833 shares worth $45.6M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets.

  • Versant Venture Management's largest Q4 2014 buy was Clovis Oncology, Inc.: 814,833 shares worth $45.6M.
  • Versant Venture Management's ten largest holdings make up 100% of its $105M portfolio in Q4 2014.
  • Versant Venture Management disclosed 5 positions in Q4 2014, its first 13F filing on record.

Based on Versant Venture Management's 13F filing for Q4 2014, filed 2 Apr 2015.